Context: Although hypothyroidism is associated with many comorbidities, the evidence for its association with all-cause mortality in older adults is limited.
H ypothyroidism is a common disease in all populations. The prevalence of overt hypothyroidism is 0.1% to 2% (1) (2) (3) (4) (5) , with the lifetime risk of overt hypothyroidism approaching 5% (6) . Primary hypothyroidism accounts for over 95% of cases of hypothyroidism, whereas central hypothyroidism from pituitary or hypothalamic failure is relatively rare. In areas of iodine sufficiency, the most common cause of primary hypothyroidism is chronic autoimmune thyroiditis (Hashimoto thyroiditis) (6, 7) . The risk factors for the development of hypothyroidism include older age, female sex (2, 6) , and genetic predisposition (8) (9) (10) .
The systemic hypometabolism associated with hypothyroidism results in a number of well-characterized metabolic changes, which manifest as hyperlipidemia, hypertension, and cardiovascular disease (11) (12) (13) (14) (15) (16) . Hypothyroidism also correlates with a higher risk of cardiac mortality and allcause mortality in the general population (15) . However, whether this correlation is valid in older individuals (i.e., individuals .65 years of age) is unclear. Grossman et al. (17) found an association between elevated serum levels of thyroid-stimulating hormone and increased mortality in older adults. However, Gussekloo et al. (18) indicated that higher levels of thyrotropin were associated with a lower rate of cardiovascular and all-cause mortality in older adults. A study conducted by van den Beld et al. (19) showed that low serum free thyroxine was associated with better 4-year survival in older men. Other studies found no association between low thyroid function and overall mortality in older adults (20) (21) (22) (23) (24) (25) .
Thyroxine replacement therapy (TRT) has been shown to alleviate the clinical and metabolic disturbances associated with hypothyroidism, thereby theoretically reducing mortality. Nevertheless, there is limited evidence to support an association between TRT and mortality in older adults with hypothyroidism (26) .
We conducted a nationwide, population-based, retrospective cohort study to determine whether hypothyroidism in older adults was associated with increased all-cause mortality and whether TRT reduces all-cause mortality in older adults with hypothyroidism.
Materials and Methods

Data sources
In 1995, Taiwan adopted a national health insurance (NHI) system, which is a government-administered, insurance-based national health care system (27) . The NHI program covers .99% of the population and contracts with 97% of the hospitals and clinics in Taiwan (28, 29) . In cooperation with the Bureau of NHI, the National Health Research Institute (NHRI) of Taiwan used a systematic random sampling method to sample a representative database of 2,000,000 patients from all NHI enrollees registered in the year 2000. This database, which was established for research purposes, is called the Longitudinal Health Insurance Database (LHID). According to the NHRI report, there were no statistically significant differences in age, sex, or health care costs between the sampling cohort and all beneficiaries in Taiwan (30) . We retrieved information about patients' characteristics and medical care records by using reimbursement claims data obtained from the LHID, including outpatients' care claims, inpatients' care claims, and the registry for beneficiaries. To protect patient privacy and data security, the NHRI encrypted the personal identification information before making the research database publicly available. This study was approved by the Institutional Review Board of Hualien Tzu Chi Hospital (IRB 105-114-C).
Study populations and matching methods
The study design featured a hypothyroidism cohort and a nonhypothyroidism cohort (the comparison cohort). Patients aged $65 years who received a new diagnosis of hypothyroidism between 2001 and 2011 were included in the hypothyroidism cohort; the date of diagnosis of hypothyroidism was considered the index date. Hypothyroidism was defined as at least one instance of inpatient diagnosis or three instances of outpatient diagnosis during the study period by using International Classification of Diseases, ninth Revision, Clinical Modification (ICD-9-CM) codes 244.8, 244.9, or 245.2. Patients with hypothyroidism with an iatrogenic etiology (surgery, radiation, or iodine) were excluded. We also excluded patients who had received a diagnosis of hypothyroidism or any other thyroid diseases in 2000 to increase the likelihood of identifying patients with newly diagnosed hypothyroidism. In addition, we excluded patients who had received a diagnosis of hyperthyroidism before the index date.
The patients comprising the nonhypothyroidism cohort were also selected from the registry of beneficiaries in the LHID. We excluded those who received a diagnosis of hypothyroidism or any other thyroid diseases (ICD-9-CM code 193, 240 to 246) during the study period. For each hypothyroidism case, 10 nonhypothyroidism patients were matched as the nonhypothyroidism cohort (control cohort) by 1:10 exact matching based on age, sex, and index year. The scale of age used to match was measured to the year.
To minimize possible selection bias caused by differences of baseline characteristics between the hypothyroidism and nonhypothyroidism cohorts, we performed 1:1 propensity score matching using the study population that was already included after initial 1:10 exact matching based on age, sex, and index year. A propensity score, which assessed the propensity for developing hypothyroidism, was calculated using a logistic regression model according to all baseline covariates listed in Table 1 . After calculating the propensity scores for every patient in the hypothyroidism and nonhypothyroidism cohorts, each patient with hypothyroidism was matched with a nonhypothyroidism patient based on the nearest-neighbor matching method without replacement, which used a caliper width equal to 0.2 times the standard deviation of the logit of the propensity score (31, 32) . The individuals in the nonhypothyroidism cohort began their follow-up visits on the same index dates as their matched cases. To ensure that the two different matching methods did not influence our results, analyses were conducted after initial 1:10 exact matching (based on age, sex, and index year) and after 1:1 propensity score matching.
Outcome measures and covariates
All study subjects were followed from the index date to the date of death or 31 December 2013 (the last date in our research database). The date of death was obtained from the National Register of Deaths in Taiwan. All-cause mortality was defined as the primary outcome and compared between the hypothyroidism and nonhypothyroidism cohorts. Cardiovascular disease (CVD) mortality was defined as the secondary outcome. Deaths recorded with ICD-9 codes 390 to 459 or ICD-10 codes I00 to I99 were classified as CVD-related deaths (33) . To further evaluate the effect of TRT on mortality in patients with hypothyroidism, we divided the hypothyroidism cohort into a TRT group and a non-TRT group. Patients in the TRT group received thyroxine for at least 30 days during the follow-up period; patients in the non-TRT group did not receive thyroxine or received thyroxine for ,30 days. The characteristics of the two groups were compared using data from the hypothyroidism cohort identified after age/sex/index year matching. Further propensity score matching did not alter the composition of the hypothyroidism cohort (Table 1) ; hence, we did not repeat the subgroup analysis after propensity score matching. To determine whether patients with different baseline characteristics had different outcomes, we analyzed patient data stratified for age, sex, and the baseline comorbidities listed in Table 1 . Comparisons were made between the hypothyroidism and nonhypothyroidism cohorts and between the TRT and non-TRT groups.
The baseline comorbidities shown in Table 1 were identified according to their respective ICD-9-CM codes: diabetes mellitus (250), hypertension (401 to 405), chronic obstructive pulmonary disease (490 to 496), congestive heart failure (428), coronary artery disease (410 to 414, 429. 
Sensitivity analyses
Two sensitivity analyses were performed. First, we conducted a sensitivity analysis using the different inclusion criteria for hypothyroidism cases: patients needed to have been diagnosed with hypothyroidism on at least three separate occasions, regardless of inpatient or outpatient service, to test the possible selection bias caused by different definitions of hypothyroidism. Second, to test whether the definition of the TRT group influenced our results, we performed a sensitivity analysis that defined the TRT group as patients with hypothyroidism receiving TRT for .90 days.
Statistical analysis
We used the x 2 test to analyze categorical variables, the Kaplan-Meier method to generate the survival curves, and the log-rank test to evaluate the differences between survival curves. We used three different Cox proportional hazards regression models to calculate the hazard ratios (HRs) and the 95% CIs for mortality, including univariate, multivariate, and stratified Cox proportional hazards regression models. The multivariate Cox proportional hazards regression model was performed with adjustment for all the baseline characteristics listed in Table 1 , and the stratified Cox proportional hazards regression model was performed with stratification for each matched pair that was generated by the two matching procedures. To investigate whether both the TRT and non-TRT groups in patients with hypothyroidism had different mortality risk compared with the patients without hypothyroidism, we performed the analyses of model 1, which calculated the HRs for the TRT and non-TRT groups by using the patients without hypothyroidism as the reference group. To further investigate whether receiving TRT altered the mortality risk within patients with hypothyroidism, we performed analyses of model 2, which calculated the HRs for only the TRT group, by using the non-TRT group as the reference. A P value ,0.05 was considered statistically significant. All statistical analyses were performed using SAS 9.4 software (SAS Institute, Inc., Cary, NC).
Results
Demographic characteristics
In our study, 2029 patients with hypothyroidism were matched to 20,290 control subjects without hypothyroidism via 1:10 matching based on age, sex, and index year (total, 22,319 patients). This exact matching procedure resulted in identical age and sex distributions between these two cohorts. However, patients with hypothyroidism had significantly more baseline comorbidities than those without hypothyroidism (Table 1) . Further, 1:1 propensity score matching produced cohorts with no significant differences in baseline comorbidities (Table 1) . Via propensity score matching, 2026 patients with hypothyroidism were matched to 2026 control subjects without hypothyroidism (total, 4052 patients).
All-cause mortality in patients with and without hypothyroidism According to the Kaplan-Meier survival curves, the hypothyroidism cohort had a significantly lower survival rate than the nonhypothyroidism cohort (log-rank test, P , 0.001 after both age/sex/index year matching [ Fig.  1(a) ] and propensity score matching [ Fig. 1(b) ]) All three Cox proportional hazards regression models revealed that older patients with hypothyroidism had an increased risk of all-cause mortality, including univariate (age/sex/ index year matching: crude HR, 2.40; 95% CI, 2.22 to 2.60; P , 0.001; propensity score matching: crude HR, 1.73; 95% CI, 1.54 to 1.94; P , 0.001), multivariate [age/sex/index year matching: adjusted HR (aHR), 1.82; 95% CI, 1.68 to 1.98; P , 0.001; propensity score matching: aHR, 1.80; 95% CI, 1.60 to 2.03; P , 0.001), and stratified Cox proportional hazards regression models (age/sex/index year matching: aHR, 1.84; 95% CI, 1.61 to 2.10; P , 0.001; propensity score matching: aHR, 1.43; 95% CI, 1.07 to 1.91; P = 0.015) ( Table 2) .
In analyses stratified according to the baseline characteristics in Table 1 , hypothyroidism was significantly associated with an increased risk of all-cause mortality regardless of age, sex, or almost all comorbidities (except chronic liver disease) in cohorts matched using either method (Supplemental Table 1 ).
The sensitivity analysis using different definitions of hypothyroidism revealed similar results. Hypothyroidism was significantly associated with an increased risk of all-cause mortality in univariate (aHR, 1.55; 95% CI, 1.38 to 1.73; P , 0.001) and multivariate (aHR, 1.18; 95% CI, 1.05 to 1.32; P = 0.007) Cox proportional hazard regression models.
All-cause mortality in patients with hypothyroidism who did or did not receive TRT
The Kaplan-Meier survival curves showed that older patients with hypothyroidism who received TRT had a significantly higher survival rate than those who did not [log-rank test, P , 0.001; Fig. 1(c) ]. Patients in the TRT group had a significantly lower risk of allcause mortality (aHR, 0.57; 95% CI, 0.49 to 0.66; P , 0.001) ( Table 3 ). This was also true in analyses stratified according to the baseline comorbidities in Table 1 , with the only exception of chronic liver disease (Supplemental Table 2 ).
However, the risk of all-cause mortality was significantly higher in both groups (TRT group: aHR, 1.40; 95% CI, 1.25 to 1.57; P , 0.001; non-TRT group: aHR, 2.46; 95% CI, 2.21-2.73; P , 0.001) than in the nonhypothyroidism cohort (Table 3) .
Sensitivity analysis using the definition of the TRT group as using .90 days of thyroxine revealed similar results. Patients in the TRT group still had a significantly lower risk of all-cause mortality (aHR, 0.51; 95% CI, 0.44 to 0.59; P , 0.001) than the non-TRT group. Compared with the nonhypothyroidism cohort, both TRT and non-TRT groups had a higher risk of all-cause mortality (TRT group: aHR, 1.23; 95% CI, 1.08 to 1.40; P = 0.001; non-TRT group: aHR, 2.45; 95% CI, 2.22 to 2.71; P , 0.001).
CVD mortality
The analyses for CVD mortality revealed similar patterns to the analyses for all-cause mortality. Patients with hypothyroidism had an increased risk of CVD mortality compared with those without hypothyroidism Figure 1 . Kaplan-Meier survival curves of (a) patients with hypothyroidism vs patients without hypothyroidism after age/sex/index year matching, (b) patients with hypothyroidism vs patients without hypothyroidism after propensity score matching, and (c) patients with hypothyroidism who received TRT vs those who did not. (Table 4) . Among patients with hypothyroidism, patients in the TRT group had a significantly lower risk of CVD mortality than the non-TRT group. Compared with the nonhypothyroidism cohort, both the TRT and non-TRT groups had higher CVD mortality risks ( Table 5 ). The survival curves of CVD mortality for comparisons between the hypothyroidism and nonhypothyroidism cohorts and between patients with hypothyroidism with and without TRT are shown in Fig. 2 .
Discussion
This nationwide, population-based, retrospective cohort study revealed that hypothyroidism was associated with an increased risk of all-cause mortality in older adults.
In patients with hypothyroidism, the risk of all-cause mortality was lower in those who received TRT than in those who did not. The results of CVD mortality revealed a similar pattern to all-cause mortality. b Per 1000 person-y.
c Model 1: aHR was calculated by using the nonhypothyroidism cohort as the reference group in a multivariate Cox proportional hazard regression model adjusting for all baseline characteristics in Table 1 . d Model 2: aHR was calculated by using hypothyroidism patients who did not receive TRT as the reference group in a multivariate Cox proportional hazard regression model adjusting for all baseline characteristics in Table 1 .
Hypothyroidism is common in older people, and its prevalence increases with age. Thyroid hormone insufficiency affects multiple organs and may result in cognitive changes and functional decline if unrecognized (34) . Previous studies found an association between hypothyroidism and all-cause mortality in older patients (17) , but other studies did not find a significant association (20) (21) (22) (23) (24) (25) ; on the other hand, other studies found that a slightly decreased thyroid function was associated with increased lifespan or better survival (18, 19) . A recent meta-analysis of observational studies, with no restrictions on age or the degree of hypothyroidism, revealed that patients with hypothyroidism had a higher risk of all-cause mortality than did those with euthyroid condition (relative risk, 1.25; 95% CI, 1.13 to 1.39) (15) . In subgroup analysis, according to the mean age of study populations, the pooled relative risks of the all-cause mortality associated with hypothyroidism b Per 1000 person-y.
c Model 1: aHR was calculated by using the nonhypothyroidism cohort as the reference group in a multivariate Cox proportional hazard regression model adjusting for all baseline characteristics in Table 1 . d Model 2: aHR was calculated by using patients with hypothyroidism who did not receive TRT as the reference group in a multivariate Cox proportional hazard regression model adjusting for all baseline characteristics in Table 1 .
was statistically significant in the study group of patients with a mean age between 65 and 79 years (relative risk, 1.15; 95% CI, 1.03 to 1.29). Our study included patients aged $65 years with no restriction on the degree of hypothyroidism. Its key finding-the association of hypothyroidism with the risk of all-cause mortality-is consistent with results of the metaanalysis by Ning et al. (15) . Moreover, we evaluated the effects of TRT on all-cause mortality in older patients with hypothyroidism, a subject that had not been well investigated previously. Patients with hypothyroidism usually have several comorbidities. Previous studies have shown that the presence of comorbidities, especially CVD, affects mortality in patients with hypothyroidism (13-15, 35, 36) . Our result for CVD mortality was consistent with previous studies. To determine whether hypothyroidism increases the risk of mortality, we used a multivariate Cox proportional hazards regression analysis adjusted for comorbidities to compare the mortality risks of comorbidity-matched patients with and without hypothyroidism; doing so allowed us to eliminate possible residual confounding effects. Even under these conditions, there was a significantly higher risk of mortality in patients with hypothyroidism. This finding indicates that hypothyroidism is a risk factor for mortality, independent of the effects of comorbidities.
A beneficial effect of TRT on patient survival was reported in a previous study (36) , but that study did not focus on older patients. The aim of TRT for hypothyroidism is to achieve a euthyroid state, but this goal carries a risk of overtreatment (37) . Repeated thyroid state evaluations should be regularly performed to assess disease status. The current study showed that older patients with hypothyroidism who undergo TRT have a lower risk of mortality than matched patients who do not. However, due to the lack of exact thyroid status in the claims-based data, we could not determine whether patients with TRT in our study have achieved euthyroid state and how this influenced mortality risk. Further prospective studies that obtain detailed information on thyroid status are needed to explore this issue.
The strengths of the current study include adequate statistical power because of a sufficient sample size and the inclusion of participants from nationwide, populationbased registers. However, this study also has some limitations. First, we could not obtain information from the LHID on potential confounding factors (e.g., lifestyle) or physical, psychiatric, or laboratory examination data (e.g., thyroid function). Although the study design included adjustment for baseline differences between groups, bias related to unknown or unmeasured confounders might still exist. Second, the patients with hypothyroidism were not randomized to thyroxine treatment but were likely treated according to disease severity, with patients with greater disease severity receiving TRT and those with less severe disease (transient or very mild hypothyroidism) not receiving TRT. Despite the possibility that the TRT group may have had more severe conditions, this group had a relatively lower mortality risk than patients who did not undergo TRT. Hence, the association between TRT and decreased mortality risk in older patients with hypothyroidism may have been underestimated. Third, potential information biases might have been introduced because of misclassification based on the ICD-9-CM diagnosis codes in the LHID. Because of the anonymization of patient data, we were unable to approach patients directly to confirm their data or the accuracy of their diagnoses. However, previous studies have reported that diagnoses based on ICD-9-CM codes in the LHID have high accuracy and validity (38, 39) . We tried to mitigate this limitation by restricting our definition of hypothyroidism to at least one instance of inpatient diagnosis or three instances of outpatient diagnosis. Moreover, in Taiwan, to ensure the accuracy of diagnoses and medical records, the Bureau of National Health Insurance routinely performs specialized crossover examinations, and hospitals or doctors are heavily fined if wrong diagnoses or coding Figure 2 . Kaplan-Meier survival curves for CVD mortality of (a) patients with hypothyroidism vs patients without hypothyroidism after age/sex/ index year matching, (b) patients with hypothyroidism vs patients without hypothyroidism after propensity score matching, and (c) patients with hypothyroidism who received TRT vs those who did not.
errors are identified (27) . This supports the diagnostic validity of our study and its results.
In summary, this population-based retrospective cohort study revealed that hypothyroidism was independently associated with a higher risk of all-cause mortality in older patients. In older patients with hypothyroidism, TRT was associated with a lower risk of all-cause mortality. Additional high-quality prospective cohort studies and randomized controlled trials are needed to further examine the effects of hypothyroidism and TRT on mortality.
